Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 20/20 | 0.65 |
| ▸ | CNR2 | P34972 | 4/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3567919 | 0.87 | CNR1 (0.70) | CNR1CNR2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL3572795 | 0.87 | CNR1 (0.70) | CNR1CNR2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL5560860 | 0.86 | CNR1 (0.68) | CNR1CNR2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL5566347 | 0.85 | CNR1 (0.68) | CNR1CNR2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL3574119 | 0.84 | CNR1 (0.66) | CNR1CNR2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL3566635 | 0.81 | CNR1 (0.63) | CNR1CNR2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL3570908 | 0.81 | CNR1 (0.63) | CNR1CNR2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL3575434 | 0.81 | CNR1 (0.54) | CNR1CNR2CYP3A4CYP2D6CYP2C9 | |
| Hydrochloric Acid SCHEMBL3573249 | 0.81 | CNR1 (0.63) | CNR1CNR2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL3565564 | 0.81 | CNR1 (0.62) | CNR1CNR2CYP3A4CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7700634-B2 | (Indol-3-yl) heterocycle derivatives as agonists of the cannabinoid CB1 receptor | N.V. ORGANON (NL) | 2010-04-20 | — | — | US | disclosed |
| EP-1725232-B1 | (INDOL-3-YL)-HETEROCYCLE DERIVATIVES AS AGONISTS OF THE CANNABINOID CB1 RECEPTOR | ORGANON NV (NL) | 2008-01-23 | — | — | EP | disclosed |
| US-20070142446-A1 | (Indol-3-yl) heterocycle derivatives as a agonists of the cannabinoid cb1 receptor | MERCK SHARP & DOHME B.V. (NL) | 2007-06-21 | — | — | US | disclosed |
| EP-1725232-A1 | (INDOL-3-YL)-HETEROCYCLE DERIVATIVES AS AGONISTS OF THE CANNABINOID CB1 RECEPTOR | N.V. Organon (NL) | 2006-11-29 | — | — | EP | disclosed |
| WO-2005089754-A1 | (INDOL-3-YL)-HETEROCYCLE DERIVATIVES AS AGONISTS OF THE CANNABINOID CB1 RECEPTOR | AKZO NOBEL N.V. (NL) | 2005-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142446-A1 | (Indol-3-yl) heterocycle derivatives as a agonists of the cannabinoid cb1 receptor | CNR1, CNR2, OPRL1 | CNR1 1/4885CNR2 2/4885CYP3A4 737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.